The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review.

Publisher: Kluwer Academic For The International Society For Cardiovascular Pharmacotherapy Country of Publication: United States NLM ID: 8712220 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7241 (Electronic) Linking ISSN: 09203206 NLM ISO Abbreviation: Cardiovasc Drugs Ther Subsets: MEDLINE

Publication: Norwell Ma : Kluwer Academic For The International Society For Cardiovascular Pharmacotherapy
Original Publication: [Norwell, MA] : Martinus Nijhoff Pub., [c1987-

Antineoplastic Agents*/adverse effects ; Cardiotoxicity*; Humans ; Protein Kinase Inhibitors/adverse effects ; Receptor, ErbB-2/metabolism ; Vascular Endothelial Growth Factor A

Aim: In recent decades, there has been a revolutionary decrease in cancer-related mortality and an increase in survival due to the introduction of novel targeted drugs. Nevertheless, drugs targeting human epidermal growth factor receptor 2 (HER-2), angiogenesis, and other tyrosine kinases also come with unexpected cardiac side effects, including heart failure, hypertension, arterial thrombosis, and arrhythmias, and have mechanisms that are unlike those of classic chemotherapeutic agents. In addition, it is challenging to address some problems, as the existing guidelines need to be more specific, and further large-scale clinical trials and experimental studies are required to confirm the benefit of administering cardioprotective agents to patients treated with targeted therapies. Therefore, an improved understanding of cardiotoxicity becomes increasingly important to minimize the pernicious effects and maximize the beneficial effects of targeted agents.
Methods: "Cardiotoxicity", "targeted drugs", "HER2", "trastuzumab", "angiogenesis inhibitor", "VEGF inhibitor" and "tyrosine kinase inhibitors" are used as keywords for article searches.
Results: In this article, we report several targeted therapies that induce cardiotoxicity and update knowledge of the clinical evidence, molecular mechanisms, and management measures.
(© 2021. Springer Science+Business Media, LLC, part of Springer Nature.)

Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. (PMID: 2805510310.3322/caac.21387)
Waks AG, Winer EP. Breast cancer treatment: a review. Jama. 2019;321(3):288–300. (PMID: 3066750510.1001/jama.2018.19323)
Leemasawat K, Phrommintikul A, Chattipakorn SC, Chattipakorn N. Mechanisms and potential interventions associated with the cardiotoxicity of ErbB2-targeted drugs: insights from in vitro, in vivo, and clinical studies in breast cancer patients. Cell Mol Life Sci. 2019;77:1571–89. (PMID: 3165018610.1007/s00018-019-03340-w)
Chen T, Xu T, Li Y, Liang C, Chen J, Lu Y, et al. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer Treat Rev. 2011;37(4):312–20. (PMID: 2095213110.1016/j.ctrv.2010.09.001)
Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23(31):7811–9. (PMID: 1625808310.1200/JCO.2005.02.4091)
Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29(25):3366–73. (PMID: 21768458316424210.1200/JCO.2011.35.0868)
Leemasawat K, Phrommintikul A, Chattipakorn SC, Chattipakorn N. Mechanisms and potential interventions associated with the cardiotoxicity of ErbB2-targeted drugs: insights from in vitro, in vivo, and clinical studies in breast cancer patients. Cell Mol Life Sci. 2020;77(8):1571–89. (PMID: 3165018610.1007/s00018-019-03340-w)
Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519–30. (PMID: 3217142610.1016/S1470-2045(19)30863-0)
Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005;23(13):2900–2. (PMID: 1586084810.1200/JCO.2005.05.827)
Barish R, Gates E, Barac A. Trastuzumab-induced cardiomyopathy. Cardiol Clin. 2019;37(4):407–18. (PMID: 3158778210.1016/j.ccl.2019.07.005)
Riccio G, Coppola C, Piscopo G, Capasso I, Maurea C, Esposito E, et al. Trastuzumab and target-therapy side effects: is still valid to differentiate anthracycline type I from type II cardiomyopathies? Hum Vaccin Immunother. 2016;12(5):1124–31. (PMID: 26836985496307110.1080/21645515.2015.1125056)
Maurea N, Coppola C, Piscopo G, Galletta F, Riccio G, Esposito E, et al. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors. J Cardiovasc Med (Hagerstown). 2016;17(Suppl 1):S19–26. (PMID: 10.2459/JCM.0000000000000377)
Rupert CE, Coulombe KL. The roles of neuregulin-1 in cardiac development, homeostasis, and disease. Biomark Insights. 2015;10(Suppl 1):1–9. (PMID: 259225714395047)
D'Uva G, Aharonov A, Lauriola M, Kain D, Yahalom-Ronen Y, Carvalho S, et al. ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation. Nat Cell Biol. 2015;17(5):627–38. (PMID: 2584874610.1038/ncb3149)
Lemmens K, Doggen K, De Keulenaer GW. Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation. 2007;116(8):954–60. (PMID: 1770965010.1161/CIRCULATIONAHA.107.690487)
Parodi EM, Kuhn B. Signalling between microvascular endothelium and cardiomyocytes through neuregulin. Cardiovasc Res. 2014;102(2):194–204. (PMID: 24477642398944810.1093/cvr/cvu021)
Jiang Z, Zhou M. Neuregulin signaling and heart failure. Curr Heart Fail Rep. 2010;7(1):42–7. (PMID: 2042549610.1007/s11897-010-0003-y)
Vermeulen Z, Segers VF, De Keulenaer GW. ErbB2 signaling at the crossing between heart failure and cancer. Basic Res Cardiol. 2016;111(6):60. (PMID: 27596216501148110.1007/s00395-016-0576-z)
Pentassuglia L, Sawyer DB. The role of Neuregulin-1beta/ErbB signaling in the heart. Exp Cell Res. 2009;315(4):627–37. (PMID: 1880136010.1016/j.yexcr.2008.08.015)
Lee JH, Yoo JY, Kim HB, Yoo HI, Song DY, Min SS, et al. Neuregulin1 attenuates H(2)O(2)-induced reductions in EAAC1 protein levels and reduces H(2)O(2)-induced oxidative stress. Neurotox Res. 2019;35(2):401–9. (PMID: 3032858410.1007/s12640-018-9965-4)
Rohrbach S, Muller-Werdan U, Werdan K, Koch S, Gellerich NF, Holtz J. Apoptosis-modulating interaction of the neuregulin/erbB pathway with anthracyclines in regulating Bcl-xS and Bcl-xL in cardiomyocytes. J Mol Cell Cardiol. 2005;38(3):485–93. (PMID: 1573390810.1016/j.yjmcc.2004.12.013)
Jie B, Zhang X, Wu X, Xin Y, Liu Y, Guo Y. Neuregulin-1 suppresses cardiomyocyte apoptosis by activating PI3K/Akt and inhibiting mitochondrial permeability transition pore. Mol Cell Biochem. 2012;370(1-2):35–43. (PMID: 2288642710.1007/s11010-012-1395-7)
Liu YQ, Yang M, Duan CH, Su GB, Wang JH, Liu YF, et al. Protective role of neuregulin-1 toward doxorubicin-induced myocardial toxicity. Genet Mol Res. 2014;13(2):4627–34. (PMID: 2503651210.4238/2014.June.18.5)
Gu X, Liu X, Xu D, Li X, Yan M, Qi Y, et al. Cardiac functional improvement in rats with myocardial infarction by up-regulating cardiac myosin light chain kinase with neuregulin. Cardiovasc Res. 2010;88(2):334–43. (PMID: 2061591610.1093/cvr/cvq223)
Samson R, Baydoun H, Jaiswal A, Le Jemtel TH. Cardiac adrenergic nervous system and left ventricular remodeling. Am J Med Sci. 2015;350(4):321–6. (PMID: 2633273010.1097/MAJ.0000000000000549)
Okoshi K, Nakayama M, Yan X, Okoshi MP, Schuldt AJ, Marchionni MA, et al. Neuregulins regulate cardiac parasympathetic activity: muscarinic modulation of beta-adrenergic activity in myocytes from mice with neuregulin-1 gene deletion. Circulation. 2004;110(6):713–7. (PMID: 1528937310.1161/01.CIR.0000138109.32748.80)
Gordon LI, Burke MA, Singh AT, Prachand S, Lieberman ED, Sun L, et al. Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J Biol Chem. 2009;284(4):2080–7. (PMID: 19017630262910710.1074/jbc.M804570200)
Gorini S, De Angelis A, Berrino L, Malara N, Rosano G, Ferraro E. Chemotherapeutic drugs and mitochondrial dysfunction: focus on doxorubicin, trastuzumab, and sunitinib. Oxidative Med Cell Longev. 2018;2018:7582730–15. (PMID: 10.1155/2018/7582730)
Siddiqa A, Long LM, Li L, Marciniak RA, Kazhdan I. Expression of HER-2 in MCF-7 breast cancer cells modulates anti-apoptotic proteins Survivin and Bcl-2 via the extracellular signal-related kinase (ERK) and phosphoinositide-3 kinase (PI3K) signalling pathways. BMC Cancer. 2008;8:129. (PMID: 18454859238647910.1186/1471-2407-8-129)
Mohan N, Shen Y, Endo Y, ElZarrad MK, Wu WJ. Trastuzumab, but not pertuzumab, dysregulates HER2 signaling to mediate inhibition of autophagy and increase in reactive oxygen species production in human cardiomyocytes. Mol Cancer Ther. 2016;15(6):1321–31. (PMID: 2719730310.1158/1535-7163.MCT-15-0741)
Mohan N, Jiang J, Wu WJ. Implications of autophagy and oxidative stress in trastuzumab-mediated cardiac toxicities. Austin Pharmacol Pharm. 2017;2(1):1005. (PMID: 302885036168002)
Janser FA, Tschan MP, Langer R. The role of autophagy in HER2-targeted therapy. Swiss Med Wkly. 2019;149:w20138. (PMID: 31656036)
Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375(9712):377–84. (PMID: 2011382510.1016/S0140-6736(09)61964-4)
Belmonte F, Das S, Sysa-Shah P, Sivakumaran V, Stanley B, Guo X, et al. ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity. Am J Physiol Heart Circ Physiol. 2015;309(8):H1271–80. (PMID: 26254336466696410.1152/ajpheart.00517.2014)
Timolati F, Ott D, Pentassuglia L, Giraud MN, Perriard JC, Suter TM, et al. Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. J Mol Cell Cardiol. 2006;41(5):845–54. (PMID: 1700519510.1016/j.yjmcc.2006.08.002)
Zeglinski M, Ludke A, Jassal DS, Singal PK. Trastuzumab-induced cardiac dysfunction: A 'dual-hit'. Exp Clin Cardiol. 2011;16(3):70–4. (PMID: 220659363209542)
Dang CT, Yu AF, Jones LW, Liu J, Steingart RM, Argolo DF, et al. Cardiac surveillance guidelines for trastuzumab-containing therapy in early-stage breast cancer: getting to the heart of the matter. J Clin Oncol. 2016;34(10):1030–3. (PMID: 26834055507055810.1200/JCO.2015.64.5515)
Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: Part 1. J Am Coll Cardiol. 2017;70(20):2536–51. (PMID: 29145954582518710.1016/j.jacc.2017.09.1096)
Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–801. (PMID: 2756740610.1093/eurheartj/ehw211)
Raschi E, Diemberger I, Cosmi B, De Ponti F. ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations. Intern Emerg Med. 2018;13(1):1–9. (PMID: 2894255010.1007/s11739-017-1755-0)
Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911–39. (PMID: 2517239910.1016/j.echo.2014.07.012)
Negishi T, Miyazaki S, Negishi K. Echocardiography and cardio-oncology. Heart Lung Circ. 2019;28(9):1331–8. (PMID: 3123086910.1016/j.hlc.2019.04.023)
Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. 2014;63(25 Pt A):2751–68. (PMID: 2470391810.1016/j.jacc.2014.01.073)
Löffler AI, Salerno M. Cardiac MRI for the evaluation of oncologic cardiotoxicity. J Nucl Cardiol. 2018;25(6):2148–58. (PMID: 29736616622200510.1007/s12350-018-1293-9)
Thirupathi A, de Souza CT. Multi-regulatory network of ROS: the interconnection of ROS, PGC-1 alpha, and AMPK-SIRT1 during exercise. J Physiol Biochem. 2017;73(4):487–94. (PMID: 2870728010.1007/s13105-017-0576-y)
Cai MX, Shi XC, Chen T, Tan ZN, Lin QQ, Du SJ, et al. Exercise training activates neuregulin 1/ErbB signaling and promotes cardiac repair in a rat myocardial infarction model. Life Sci. 2016;149:1–9. (PMID: 2689214610.1016/j.lfs.2016.02.055)
Ohtani K, Ide T, Hiasa KI, Sakamoto I, Yamashita N, Kubo M, et al. Cardioprotective effect of renin-angiotensin inhibitors and β-blockers in trastuzumab-related cardiotoxicity. Clin Res Cardiol. 2019;108(10):1128–39. (PMID: 3085938110.1007/s00392-019-01448-4)
Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, de Caralt TM, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013;61(23):2355–62. (PMID: 2358376310.1016/j.jacc.2013.02.072)
Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr, das Dores Cruz F, Gonçalves Brandão SM, Rigaud VOC, et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: The CECCY Trial. J Am Coll Cardiol. 2018;71(20):2281–90. (PMID: 2954032710.1016/j.jacc.2018.02.049)
Calvillo-Argüelles O, Abdel-Qadir H, Michalowska M, Billia F, Suntheralingam S, Amir E, et al. Cardioprotective effect of statins in patients with HER2-positive breast cancer receiving trastuzumab therapy. Can J Cardiol. 2019;35(2):153–9. (PMID: 3076042110.1016/j.cjca.2018.11.028)
Cho DH, Lim IR, Kim JH, Kim MN, Kim YH, Park KH, et al. Protective effects of statin and angiotensin receptor blocker in a rat model of doxorubicin- and trastuzumab-induced cardiomyopathy. J Am Soc Echocardiogr. 2020;33(10):1253–63. (PMID: 3277849810.1016/j.echo.2020.05.021)
Kabel AM, Elkhoely AA. Targeting proinflammatory cytokines, oxidative stress, TGF-β1 and STAT-3 by rosuvastatin and ubiquinone to ameliorate trastuzumab cardiotoxicity. Biomed Pharmacother. 2017;93:17–26. (PMID: 2862259110.1016/j.biopha.2017.06.033)
Davis MK, Virani SA. Statins in cardio-oncology: holy grail or epiphenomenon. Can J Cardiol. 2019;35(2):142–4. (PMID: 3063913410.1016/j.cjca.2018.12.026)
Ozturk M, Ozler M, Kurt YG, Ozturk B, Uysal B, Ersoz N, et al. Efficacy of melatonin, mercaptoethylguanidine and 1400W in doxorubicin- and trastuzumab-induced cardiotoxicity. J Pineal Res. 2011;50(1):89–96. (PMID: 2106235010.1111/j.1600-079X.2010.00818.x)
Riccio G, Antonucci S, Coppola C, D'Avino C, Piscopo G, Fiore D, et al. Ranolazine attenuates trastuzumab-induced heart dysfunction by modulating ROS production. Front Physiol. 2018;9:38. (PMID: 29467663580816510.3389/fphys.2018.00038)
Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349(5):427–34. (PMID: 12890841227532410.1056/NEJMoa021491)
Abdel-Qadir H, Ethier JL, Lee DS, Thavendiranathan P, Amir E. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis. Cancer Treat Rev. 2017;53:120–7. (PMID: 2810456710.1016/j.ctrv.2016.12.002)
Totzeck M, Mincu RI, Rassaf T. Cardiovascular adverse events in patients with cancer treated with bevacizumab: a meta-analysis of more than 20 000 patients. J Am Heart Assoc. 2017;6(8):e006278. (PMID: 28862931558646210.1161/JAHA.117.006278)
Totzeck M, Mincu RI, Mrotzek S, Schadendorf D, Rassaf T. Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: a meta-analysis of approximately 29,000 cancer patients. Eur J Prev Cardiol. 2018;25(5):482–94. (PMID: 2937675310.1177/2047487318755193)
Touyz RM, Herrmann SMS, Herrmann J. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. J Am Soc Hypertens. 2018;12(6):409–25. (PMID: 29703600616878410.1016/j.jash.2018.03.008)
Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010;102(9):596–604. (PMID: 20351338286429010.1093/jnci/djq091)
Budolfsen C, Faber J, Grimm D, Krüger M, Bauer J, Wehland M, et al. Tyrosine kinase inhibitor-induced hypertension: role of hypertension as a biomarker in cancer treatment. Curr Vasc Pharmacol. 2019;17(6):618–34. (PMID: 3070681810.2174/1570161117666190130165810)
Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009;6(6):327–38. (PMID: 19483739305743310.1038/nrclinonc.2009.63)
Melincovici CS, Boşca AB, Şuşman S, Mărginean M, Mihu C, Istrate M, et al. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. Romanian J Morphol Embryol. 2018;59(2):455–67.
Lankhorst S, Saleh L, Danser AJ, van den Meiracker AH. Etiology of angiogenesis inhibition-related hypertension. Curr Opin Pharmacol. 2015;21:7–13. (PMID: 2550020610.1016/j.coph.2014.11.010)
Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358(19):2039–49. (PMID: 18463380454200910.1056/NEJMra0706596)
Galvano A, Guarini A, Iacono F, Castiglia M, Rizzo S, Tarantini L, et al. An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy. Expert Opin Drug Saf. 2019;18(6):485–96. (PMID: 3106299110.1080/14740338.2019.1613371)
Nagai A, Sado T, Naruse K, Noguchi T, Haruta S, Yoshida S, et al. Antiangiogenic-induced hypertension: the molecular basis of signaling network. Gynecol Obstet Investig. 2012;73(2):89–98. (PMID: 10.1159/000334458)
Li M, Kroetz DL. Bevacizumab-induced hypertension: clinical presentation and molecular understanding. Pharmacol Ther. 2018;182:152–60. (PMID: 2888253710.1016/j.pharmthera.2017.08.012)
Neagoe PE, Lemieux C, Sirois MG. Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer. J Biol Chem. 2005;280(11):9904–12. (PMID: 1563707110.1074/jbc.M412017200)
Lankhorst S, Kappers MH, van Esch JH, Danser AH, van den Meiracker AH. Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1. J Hypertens. 2013;31(3):444–54 discussion 54. (PMID: 2322198710.1097/HJH.0b013e32835c1d1b)
Kruzliak P, Novák J, Novák M. Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors. Am J Hypertens. 2014;27(1):3–13. (PMID: 2416891510.1093/ajh/hpt201)
Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol. 2016;17(10):611–25. (PMID: 2746139110.1038/nrm.2016.87)
Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006;7(5):359–71. (PMID: 1663333810.1038/nrm1911)
Bates DO. Vascular endothelial growth factors and vascular permeability. Cardiovasc Res. 2010;87(2):262–71. (PMID: 20400620289554110.1093/cvr/cvq105)
Matsumoto K, Ema M. Roles of VEGF-A signalling in development, regeneration, and tumours. J Biochem. 2014;156(1):1–10. (PMID: 2483929510.1093/jb/mvu031)
Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011–27. (PMID: 1558575410.1200/JCO.2005.06.081)
Lankhorst S, Danser AH, van den Meiracker AH. Endothelin-1 and antiangiogenesis. Am J Physiol Regul Integr Comp Physiol. 2016;310(3):R230–4. (PMID: 2651152310.1152/ajpregu.00373.2015)
Neves KB, Rios FJ, van der Mey L, Alves-Lopes R, Cameron AC, Volpe M, et al. VEGFR (vascular endothelial growth factor receptor) inhibition induces cardiovascular damage via redox-sensitive processes. Hypertension. 2018;71(4):638–47. (PMID: 2948322810.1161/HYPERTENSIONAHA.117.10490)
Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, et al. Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease. Hypertension. 2018;71(2):e1–8. (PMID: 2927931110.1161/HYPERTENSIONAHA.117.10271)
Konukoglu D, Uzun H. Endothelial dysfunction and hypertension. Adv Exp Med Biol. 2017;956:511–40. (PMID: 2803558210.1007/5584_2016_90)
Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension. 2009;54(3):652–8. (PMID: 1965208410.1161/HYPERTENSIONAHA.109.129973)
Steeghs N, Rabelink TJ, op't Roodt J, Batman E, Cluitmans FH, Weijl NI, et al. Reversibility of capillary density after discontinuation of bevacizumab treatment. Ann Oncol. 2010;21(5):1100–5. (PMID: 1985472110.1093/annonc/mdp417)
Beaini S, Saliba Y, Hajal J, Smayra V, Bakhos JJ, Joubran N, et al. VEGF-C attenuates renal damage in salt-sensitive hypertension. J Cell Physiol. 2019;234(6):9616–30. (PMID: 3037810810.1002/jcp.27648)
Kappers MH, de Beer VJ, Zhou Z, Danser AH, Sleijfer S, Duncker DJ, et al. Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension. 2012;59(1):151–7. (PMID: 2212443210.1161/HYPERTENSIONAHA.111.182220)
Versmissen J, Mirabito Colafella KM, Koolen SLW, Danser AHJ. Vascular cardio-oncology: vascular endothelial growth factor inhibitors and hypertension. Cardiovasc Res. 2019;115(5):904–14. (PMID: 3072688210.1093/cvr/cvz022)
Steingart RM, Bakris GL, Chen HX, Chen MH, Force T, Ivy SP, et al. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J. 2012;163(2):156–63. (PMID: 2230583110.1016/j.ahj.2011.10.018)
Caletti S, Paini A, Coschignano MA, De Ciuceis C, Nardin M, Zulli R, et al. Management of VEGF-targeted therapy-induced hypertension. Curr Hypertens Rep. 2018;20(8):68. (PMID: 2995959310.1007/s11906-018-0871-1)
Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension. 2020;75(6):1334–57. (PMID: 3237057210.1161/HYPERTENSIONAHA.120.15026)
McKay RR, Rodriguez GE, Lin X, Kaymakcalan MD, Hamnvik OP, Sabbisetti VS, et al. Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015;21(11):2471–9. (PMID: 25724518456685410.1158/1078-0432.CCR-14-2332)
Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol. 2009;20(5):807–15. (PMID: 1915094910.1093/annonc/mdn713)
Qi WX, Fu S, Zhang Q, Guo XM. Bevacizumab increases the risk of severe congestive heart failure in cancer patients: an up-to-date meta-analysis with a focus on different subgroups. Clin Drug Investig. 2014;34(10):681–90. (PMID: 2509684810.1007/s40261-014-0222-1)
Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest. 2005;115(8):2108–18. (PMID: 16075055118054110.1172/JCI24682)
Kim S, Ding W, Zhang L, Tian W, Chen S. Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials. Onco Targets Ther. 2014;7:719–28. (PMID: 248727134026584)
Chintalgattu V, Ai D, Langley RR, Zhang J, Bankson JA, Shih TL, et al. Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. J Clin Invest. 2010;120(2):472–84. (PMID: 20071776281007610.1172/JCI39434)
Yue Z, Chen J, Lian H, Pei J, Li Y, Chen X, et al. PDGFR-β signaling regulates cardiomyocyte proliferation and myocardial regeneration. Cell Rep. 2019;28(4):966–78.e4. (PMID: 3134015710.1016/j.celrep.2019.06.065)
Kerkela R, Woulfe KC, Durand JB, Vagnozzi R, Kramer D, Chu TF, et al. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci. 2009;2(1):15–25. (PMID: 20376335284914210.1111/j.1752-8062.2008.00090.x)
Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7(5):332–44. (PMID: 1745730110.1038/nrc2106)
Arad M, Seidman CE, Seidman JG. AMP-activated protein kinase in the heart: role during health and disease. Circ Res. 2007;100(4):474–88. (PMID: 1733243810.1161/01.RES.0000258446.23525.37)
Zhang P, Hu X, Xu X, Fassett J, Zhu G, Viollet B, et al. AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension. 2008;52(5):918–24. (PMID: 1883862610.1161/HYPERTENSIONAHA.108.114702)
Qi WX, Shen Z, Tang LN, Yao Y. Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis. Crit Rev Oncol Hematol. 2014;92(2):71–82. (PMID: 2487843310.1016/j.critrevonc.2014.04.004)
Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99(16):1232–9. (PMID: 1768682210.1093/jnci/djm086)
Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. Jama. 2008;300(19):2277–85. (PMID: 1901791410.1001/jama.2008.656)
Patel JN, Jiang C, Hertz DL, Mulkey FA, Owzar K, Halabi S, et al. Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer. 2015;121(7):1025–31. (PMID: 2541777510.1002/cncr.29169)
Ferroni P, Formica V, Roselli M, Guadagni F. Thromboembolic events in patients treated with anti-angiogenic drugs. Curr Vasc Pharmacol. 2010;8(1):102–13. (PMID: 1948590310.2174/157016110790226660)
Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96(12):1788–95. (PMID: 17519900235996210.1038/sj.bjc.6603813)
Arima Y, Oshima S, Noda K, Fukushima H, Taniguchi I, Nakamura S, et al. Sorafenib-induced acute myocardial infarction due to coronary artery spasm. J Cardiol. 2009;54(3):512–5. (PMID: 1994433310.1016/j.jjcc.2009.03.009)
Kattoor AJ, Pothineni NVK, Palagiri D, Mehta JL. Oxidative stress in atherosclerosis. Curr Atheroscler Rep. 2017;19(11):42. (PMID: 2892105610.1007/s11883-017-0678-6)
Kattoor AJ, Kanuri SH, Mehta JL. Role of Ox-LDL and LOX-1 in atherogenesis. Curr Med Chem. 2019;26(9):1693–700. (PMID: 2973724610.2174/0929867325666180508100950)
Oduk Y, Zhu W, Kannappan R, Zhao M, Borovjagin AV, Oparil S, et al. VEGF nanoparticles repair the heart after myocardial infarction. Am J Physiol Heart Circ Physiol. 2018;314(2):H278–h84. (PMID: 2910117610.1152/ajpheart.00471.2017)
Badimon L, Borrell M. Microvasculature recovery by angiogenesis after myocardial infarction. Curr Pharm Des. 2018;24(25):2967–73. (PMID: 2996233510.2174/1381612824666180629162726)
Yang Y, Shi C, Hou X, Zhao Y, Chen B, Tan B, et al. Modified VEGF targets the ischemic myocardium and promotes functional recovery after myocardial infarction. J Control Release. 2015;213:27–35. (PMID: 2614435110.1016/j.jconrel.2015.06.036)
Chen N, Ren M, Li R, Deng X, Li Y, Yan K, et al. Bevacizumab promotes venous thromboembolism through the induction of PAI-1 in a mouse xenograft model of human lung carcinoma. Mol Cancer. 2015;14:140. (PMID: 26215730451741810.1186/s12943-015-0418-x)
Adams V, Reich B, Uhlemann M, Niebauer J. Molecular effects of exercise training in patients with cardiovascular disease: focus on skeletal muscle, endothelium, and myocardium. Am J Physiol Heart Circ Physiol. 2017;313(1):H72–h88. (PMID: 2847692410.1152/ajpheart.00470.2016)
Beck EB, Erbs S, Möbius-Winkler S, Adams V, Woitek FJ, Walther T, et al. Exercise training restores the endothelial response to vascular growth factors in patients with stable coronary artery disease. Eur J Prev Cardiol. 2012;19(3):412–8. (PMID: 2145056910.1177/1741826711403068)
Hotta K, Chen B, Behnke BJ, Ghosh P, Stabley JN, Bramy JA, et al. Exercise training reverses age-induced diastolic dysfunction and restores coronary microvascular function. J Physiol. 2017;595(12):3703–19. (PMID: 28295341547136110.1113/JP274172)
Mitsuhashi T, Uemoto R, Ishikawa K, Yoshida S, Ikeda Y, Yagi S, et al. Endothelial nitric oxide synthase-independent pleiotropic effects of pitavastatin against atherogenesis and limb ischemia in mice. J Atheroscler Thromb. 2018;25(1):65–80. (PMID: 28592707577022510.5551/jat.37747)
Chen Y, Zhang S, Peng G, Yu J, Liu T, Meng R, et al. Endothelial NO synthase and reactive oxygen species mediated effect of simvastatin on vessel structure and function: pleiotropic and dose-dependent effect on tumor vascular stabilization. Int J Oncol. 2013;42(4):1325–36. (PMID: 2342638710.3892/ijo.2013.1833)
Brown JR, Moslehi J, O'Brien S, Ghia P, Hillmen P, Cymbalista F, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017;102(10):1796–805. (PMID: 28751558562286410.3324/haematol.2017.171041)
Caldeira D, Alves D, Costa J, Ferreira JJ, Pinto FJ. Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis. PLoS One. 2019;14(2):e0211228. (PMID: 30785921638209510.1371/journal.pone.0211228)
McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124(25):3829–30. (PMID: 2549845410.1182/blood-2014-10-604272)
Ganatra S, Sharma A, Shah S, Chaudhry GM, Martin DT, Neilan TG, et al. Ibrutinib-associated atrial fibrillation. JACC Clin Electrophysiol. 2018;4(12):1491–500. (PMID: 3057311110.1016/j.jacep.2018.06.004)
Jiang L, Li L, Ruan Y, Zuo S, Wu X, Zhao Q, et al. Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium. Heart Rhythm. 2019;16(9):1374–82. (PMID: 3095920310.1016/j.hrthm.2019.04.008)
Yang X, An N, Zhong C, Guan M, Jiang Y, Li X, et al. Enhanced cardiomyocyte reactive oxygen species signaling promotes ibrutinib-induced atrial fibrillation. Redox Biol. 2020;30:101432. (PMID: 31986467699471410.1016/j.redox.2020.101432)
Isaac K, Mato AR. Acalabrutinib and its therapeutic potential in the treatment of chronic lymphocytic leukemia: a short review on emerging data. Cancer Manag Res. 2020;12:2079–85. (PMID: 32256115709015110.2147/CMAR.S219570)
Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323–32. (PMID: 2664113710.1056/NEJMoa1509981)
Shafaattalab S, Lin E, Christidi E, Huang H, Nartiss Y, Garcia A, et al. Ibrutinib displays atrial-specific toxicity in human stem cell-derived cardiomyocytes. Stem Cell Rep. 2019;12(5):996–1006. (PMID: 10.1016/j.stemcr.2019.03.011)
January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125–e51. (PMID: 3068604110.1161/CIR.0000000000000665)
Caron F, Leong DP, Hillis C, Fraser G, Siegal D. Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. Blood Adv. 2017;1(12):772–8. (PMID: 29296721572805010.1182/bloodadvances.2016001883)
Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739–45. (PMID: 26059948452806410.1182/blood-2015-03-635326)
Shatzel JJ, Olson SR, Tao DL, McCarty OJT, Danilov AV, DeLoughery TG. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost. 2017;15(5):835–47. (PMID: 28182323615291410.1111/jth.13651)
Kloth JS, Pagani A, Verboom MC, Malovini A, Napolitano C, Kruit WH, et al. Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors. Br J Cancer. 2015;112(6):1011–6. (PMID: 25742483436690510.1038/bjc.2015.82)
Coppola C, Rienzo A, Piscopo G, Barbieri A, Arra C, Maurea N. Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs. Cancer Treat Rev. 2018;63:135–43. (PMID: 2930446310.1016/j.ctrv.2017.11.009)
Zang J, Wu S, Tang L, Xu X, Bai J, Ding C, et al. Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis. PLoS One. 2012;7(2):e30353. (PMID: 22363427328182610.1371/journal.pone.0030353)
Liu Y, Liu Y, Fan ZW, Li J, Xu GG. Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib. Eur J Clin Pharmacol. 2015;71(5):541–7. (PMID: 2575329110.1007/s00228-015-1831-1)
Wallace E, Howard L, Liu M, O'Brien T, Ward D, Shen S, et al. Long QT syndrome: genetics and future perspective. Pediatr Cardiol. 2019;40(7):1419–30. (PMID: 31440766678559410.1007/s00246-019-02151-x)
Foo B, Williamson B, Young JC, Lukacs G, Shrier A. hERG quality control and the long QT syndrome. J Physiol. 2016;594(9):2469–81. (PMID: 26718903485019710.1113/JP270531)
El-Sherif N, Turitto G, Boutjdir M. Acquired long QT syndrome and torsade de pointes. Pacing Clin Electrophysiol. 2018;41(4):414–21. (PMID: 2940531610.1111/pace.13296)
Roden DM. A current understanding of drug-induced QT prolongation and its implications for anticancer therapy. Cardiovasc Res. 2019;115(5):895–903. (PMID: 30689740796770510.1093/cvr/cvz013)
He S, Moutaoufik MT, Islam S, Persad A, Wu A, Aly KA, et al. HERG channel and cancer: a mechanistic review of carcinogenic processes and therapeutic potential. Biochim Biophys Acta Rev Cancer. 1873;2020(2):188355. (PMID: 10.1016/j.bbcan.2020.188355)
Cubeddu LX. Drug-induced inhibition and trafficking disruption of ion channels: pathogenesis of QT abnormalities and drug-induced fatal arrhythmias. Curr Cardiol Rev. 2016;12(2):141–54. (PMID: 26926294486194310.2174/1573403X12666160301120217)
Dennis A, Wang L, Wan X, Ficker E. hERG channel trafficking: novel targets in drug-induced long QT syndrome. Biochem Soc Trans. 2007;35(Pt 5):1060–3. (PMID: 1795627910.1042/BST0351060)
Lu Z, Wu CY, Jiang YP, Ballou LM, Clausen C, Cohen IS, et al. Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome. Sci Transl Med. 2012;4(131):131ra50. (PMID: 22539774349428210.1126/scitranslmed.3003623)
Yang T, Meoli DF, Moslehi J, Roden DM. Inhibition of the α-subunit of phosphoinositide 3-kinase in heart increases late sodium current and is arrhythmogenic. J Pharmacol Exp Ther. 2018;365(3):460–6. (PMID: 29563327593143610.1124/jpet.117.246157)
Cohen IS, Lin RZ, Ballou LM. Acquired long QT syndrome and phosphoinositide 3-kinase. Trends Cardiovasc Med. 2017;27(7):451–9. (PMID: 28687226558201310.1016/j.tcm.2017.05.005)
Lu Z, Jiang YP, Wu CY, Ballou LM, Liu S, Carpenter ES, et al. Increased persistent sodium current due to decreased PI3K signaling contributes to QT prolongation in the diabetic heart. Diabetes. 2013;62(12):4257–65. (PMID: 23974924383703110.2337/db13-0420)
Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: Part 2. J Am Coll Cardiol. 2017;70(20):2552–65. (PMID: 29145955582518810.1016/j.jacc.2017.09.1095)
Shah SR, Park K, Alweis R. Long QT syndrome: a comprehensive review of the literature and current evidence. Curr Probl Cardiol. 2019;44(3):92–106. (PMID: 2978453310.1016/j.cpcardiol.2018.04.002)

ZR2020MH016 Natural Science Foundation of Shandong Province (CN); J18KA285 The Project of Shandong Province Higher Educational Science and Technology Program

Keywords: Angiogenesis inhibitors; Cardiotoxicity; Targeted drugs; Trastuzumab; Tyrosine kinase inhibitors

0 (Antineoplastic Agents)
0 (Protein Kinase Inhibitors)
0 (Vascular Endothelial Growth Factor A)
EC 2.7.10.1 (ERBB2 protein, human)
EC 2.7.10.1 (Receptor, ErbB-2)

Date Created: 20210413 Date Completed: 20220512 Latest Revision: 20220526

20221213

10.1007/s10557-021-07181-3

33847848